Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:39 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors
NCT02484638 · CSL Behring · PHASE2/PHASE3 · terminated · last registry update 2019-08-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Business decision non-safety related.” | – | Registry record, CSL Behring |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against F7 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-07-31Results posted on the registry: Bioverativ, a Sanofi company, rFIXFc (NCT02234310)
- 2020-07-28Phase 3 first posted: Catalyst Biosciences, MarzAA (NCT04489537)
- 2020-06-16Results posted on the registry: PTC Therapeutics, Ataluren (NCT00947193)
- 2020-06-16Also stopped (terminated): PTC Therapeutics, Ataluren (NCT00947193)
- 2020-05-19Results posted on the registry: Pfizer, SPK-9001 (NCT02484092)
- 2019-10-22Also stopped (withdrawn): Bayer, BAY1093884 (NCT03996486)
- 2019-09-06Results posted on the registry: Laboratoire français de Fractionnement et de Biotechnologies, Coagulation Factor VIIa (Recombinant) (NCT02548143)
- 2019-05-06Phase 3 first posted: Pfizer, PF-06741086 (NCT03938792)
- 2019-05-02Phase 3 first posted: AryoGen Pharmed Co., Biosimilar eptacog alfa, activated (AryoSeven) + Eptacog alfa, activated (Novoseven) (NCT03935334)
- 2019-04-11Results posted on the registry: Medexus Pharma, Inc., IB1001 (NCT01271868)
- 2019-03-12Also stopped (terminated): Spark Therapeutics, Inc., AAV8-hFIX19 (NCT01620801)
- 2019-03-04Phase 3 first posted: Pfizer, PF-06838435/ fidanacogene elaparvovec (NCT03861273)
- 2019-02-26Phase 3 first posted: Medexus Pharma, Inc., APVO101 (NCT03855280)
- 2019-01-18Phase 3 first posted: Aspen Global Incorporated, Danaparoid Sodium + Argatroban (NCT03809481)
- 2019-01-04Results posted on the registry: Novo Nordisk A/S, a drug against F7 (NCT02541942)
- 2018-11-23Results posted on the registry: Bioverativ Therapeutics Inc., rFIXFc (NCT01425723)
- 2018-11-14Results posted on the registry: Ultragenyx Pharmaceutical Inc, DTX101 (NCT02618915)
- 2018-11-14Also stopped (terminated): Ultragenyx Pharmaceutical Inc, DTX101 (NCT02618915)
- 2018-10-10Also stopped (withdrawn): Helsinki University Central Hospital, PCC + FFP (NCT01910675)
- 2018-09-10Results posted on the registry: Baxalta now part of Shire, BAX 326 (Recombinant factor IX) (NCT01286779)
- 2018-09-10Results posted on the registry: Medexus Pharma, Inc., IB1001 + nonacog alfa (NCT00768287)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision